Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
SNY [NYSE]
Sanofi
Index- P/E28.34 EPS (ttm)2.00 Insider Own- Shs Outstand2.64B Perf Week0.46%
Market Cap149.50B Forward P/E14.76 EPS next Y3.84 Insider Trans- Shs Float2.37B Perf Month7.39%
Income5.35B PEG3.30 EPS next Q- Inst Own9.10% Short Float0.08% Perf Quarter3.98%
Sales42.95B P/S3.48 EPS this Y-25.60% Inst Trans0.51% Short Ratio1.69 Perf Half Y15.79%
Book/sh25.47 P/B2.23 EPS next Y10.98% ROA4.20% Target Price60.11 Perf Year15.58%
Cash/sh2.12 P/C26.78 EPS next 5Y8.60% ROE7.50% 52W Range45.40 - 57.26 Perf YTD9.55%
Dividend1.91 P/FCF- EPS past 5Y-1.10% ROI6.10% 52W High-1.00% Beta1.04
Dividend %3.37% Quick Ratio1.40 Sales past 5Y2.90% Gross Margin67.10% 52W Low24.85% ATR0.69
Employees112128 Current Ratio1.40 Sales Q/Q0.70% Oper. Margin20.90% RSI (14)65.88 Volatility0.78% 1.01%
OptionableYes Debt/Eq0.29 EPS Q/Q72.70% Profit Margin12.50% Rel Volume0.77 Prev Close56.98
ShortableYes LT Debt/Eq0.20 EarningsFeb 09 BMO Payout41.60% Avg Volume1.10M Price56.69
Recom1.70 SMA202.45% SMA506.14% SMA20010.59% Volume854,233 Change-0.51%
03-Aug-12Downgrade Standpoint Research Buy → Hold
11-Jan-11Downgrade Jefferies Buy → Hold
16-Nov-09Initiated Deutsche Securities Buy
14-Oct-09Upgrade UBS Sell → Neutral
28-Aug-09Upgrade JP Morgan Neutral → Overweight
29-Jun-09Downgrade JP Morgan Overweight → Neutral
28-May-09Upgrade Citigroup Hold → Buy
30-Apr-09Upgrade JP Morgan Neutral → Overweight
23-Mar-09Upgrade Jefferies & Co Underperform → Hold
17-Mar-09Initiated Credit Suisse Outperform
19-Feb-09Upgrade JP Morgan Underweight → Neutral
26-Jan-09Initiated Jefferies & Co Underperform
07-Nov-08Downgrade UBS Neutral → Sell
23-Sep-08Downgrade Credit Suisse Neutral → Underperform
24-Oct-07Initiated Bernstein Mkt Perform
06-Sep-07Initiated UBS Neutral
18-Jul-07Upgrade HSBC Securities Neutral → Overweight
14-Jun-07Reiterated Banc of America Sec Buy $50 → $48
14-Jun-07Downgrade JP Morgan Overweight → Neutral
14-Jun-07Downgrade HSBC Securities Overweight → Neutral
18-Sep-14 05:24PM  Today's Market Thorns, Roses and All Time Highs... Yahoo Finance Blogs
04:35PM  Sanofi & MyoKardia Ink Deal to Develop Cardiomyopathies Zacks
17-Sep-14 05:12PM  The Market's Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
08:34AM  Sanofi and MyoKardia Announce Groundbreaking Collaboration to Develop Targeted Therapies for Patients with Genetic Heart Disease PR Newswire
16-Sep-14 09:30AM  Source Looks to Bring Europe ETF Success to the U.S. ETF Trends
15-Sep-14 11:04AM  2 Solid Picks for a Weak Euro at Forbes
12-Sep-14 05:36PM  Today's Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
04:30PM  Sanofi Reports Data on Multiple Sclerosis Drug Lemtrada Zacks
11-Sep-14 05:45PM  Eli Lilly/Boehringer's Insulin Biosimilar Gains EU Approval Zacks
01:00AM  At Four Years, Treatment Effect Maintained in More Than Two-Thirds of Patients Who Received Genzymes Lemtrada in Pivotal Studies Business Wire
10-Sep-14 05:43PM  The Market's Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
11:58AM  ReceptosMS Drug Yields More Good Data; Stock Jumps at Investor's Business Daily
11:58AM  Receptos MS Drug Yields More Good Data; Stock Jumps at Investor's Business Daily
08:00AM  Peregrine Pharmaceuticals' Q1 Loss Wider than Expected Zacks
08:00AM  Genzyme Announces Launch of Expression of Hope III Program to Build Awareness of Lysosomal Storage Disorders Through Works of Art Business Wire
06:15AM  Investment, Un-American Style at Forbes
08-Sep-14 02:14PM  FDA Approves Use of Menactra® Vaccine for Booster Immunization Against Potentially Deadly Disease PR Newswire
10:56AM  Why Illumina (ILMN) Stock Is Gaining Today at TheStreet
08:00AM  Genzyme to Feature Multiple Sclerosis Pipeline and Present New Data on Aubagio and Lemtrada at ECTRIMS Business Wire
04-Sep-14 08:00PM  [video] Regeneron Rises, Norwegian Cruises and CVS Health Quits the Habit at TheStreet
05:28PM  Today's Market Thorns, Roses, and All Time Highs Yahoo Finance Blogs
05:00PM  Amgen Seeks EU Approval for PCSK9 Inhibitor Evolocumab Zacks
03-Sep-14 05:40PM  Sanofi Reports Positive Phase III Data on Dengue Vaccine Zacks
12:02PM  First Vaccine for Dengue Fever Shows Promise in 2nd Big Trial at New York Times
10:32AM  Sanofi: First Heart Disease, Now Dengue Fever at Barrons.com
02-Sep-14 06:04PM  Novartis, Regeneron Shares Advance To New Highs On Updated Drug News Investor's Business Daily
04:19PM  Why Jim Cramer Likes Regeneron (REGN) Stock Over Sanofi (SNY) at TheStreet
03:30PM  Regeneron/Sanofi Presents Encouraging Alirocumab Data Zacks
03:04PM  [video] Jim Cramer Says Regeneron is a Better Way to Play it Than Sanofi at TheStreet
12:10PM  Regeneron: Solid Trial Takes Targets Up, Up, Up at Barrons.com
11:19AM  Novartis, Regeneron Hit New Highs On Cardio Drugs at Investor's Business Daily
11:13AM  How Will Regeneron Pharmaceuticals (REGN) Stock Be Affected By This Coverage? at TheStreet
10:48AM  Jim Cramer's Mad Dash: Regeneron to $400; Conn's a No-Touch at TheStreet
10:29AM  Cramer sees 'breakout' for this stock at CNBC
09:53AM  [video] Regeneron Shares Trend Higher on Cholesterol-Lowering Results at TheStreet
08:30AM  Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients PR Newswire
31-Aug-14 06:36PM  Cholesterol Drug Halves Heart Attack and Stroke in Early Test at New York Times
01:28PM  Early Hint At Cardiovascular Outcomes With Sanofi's and Regeneron's Rapidly Advancing Cholesterol Drug at Forbes
11:33AM  SIGNIFY Trial Provokes Sound And Fury Over Controversial Servier and Amgen Drug at Forbes
03:00AM  Sanofi and Regeneron Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress 2014 PR Newswire
03:00AM  Regeneron and Sanofi Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress 2014 PR Newswire
29-Aug-14 05:30PM  Regeneron Pharmaceuticals' Pipeline Progress Raises Costs Zacks
28-Aug-14 03:17PM  Amgen: Why Its New Drug Application is a Big Deal at Barrons.com
03:17PM  Amgen: Why Its New Drug Application is a Bid Deal at Barrons.com
10:38AM  There Are 2000 Reasons For Continued Optimism In The Stock Market at Forbes
08:25AM  The Zacks Analyst Blog Highlights: RadioShack, Amicus Therapeutics, Sanofi, Shire and Gilead Sciences Zacks
27-Aug-14 07:00AM  Where Are the Opportunities in U.S. Health Care? Morningstar
03:17AM  Return to Behemoth Stocks Yahoo Finance Blogs
25-Aug-14 04:03PM  The 4 Companies Teaming Up For A New Tool To Fight Cancer Benzinga
11:40AM  InterMune Stock Spikes On Rare Big Biotech Buyout at Investor's Business Daily
01:00AM  Regeneron and Sanofi to Present Results from Four Phase 3 Alirocumab Trials in Hot Line Session at ESC Congress 2014 PR Newswire
22-Aug-14 05:15PM  Covance Retains Balanced View on Steady Growth Zacks
04:00PM  AstraZeneca Updates on PLATO Study Investigation on Brilinta Zacks
08:24AM  Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day Zacks
21-Aug-14 03:55PM  Amicus Therapeutics (FOLD) Soars on Fabry Drug Trial Results Zacks
03:47PM  5 companies that will benefit from ALS awareness at MarketWatch
02:30PM  Illumina Partners with AstraZeneca, Sanofi, Janssen in NGS Zacks
12:03PM  Video: Illumina Partners With Big Pharma Firms at Investor's Business Daily
12:03PM  Illumina Forms Partnerships With Big Pharma Firms at Investor's Business Daily
02:00AM  Illumina Partners With Big PharmaTo Create New Genetic Tests For Cancer at Forbes
02:00AM  Illumina Partners With Big Pharma To Create New Genetic Tests For Cancer at Forbes
20-Aug-14 05:30PM  Sanofi's (SNY) Cerdelga FDA Approved for Gaucher Disease Zacks
06:05AM  Amicus Releases Study Results On Rare Disease Drug at Forbes
06:05AM  Amicus Releases Strongly Positive Study Results On Rare Disease Drug at Forbes
06:05AM  Amicus Releases Positive Study Results On Rare Disease Drug at Forbes
06:01AM  Yes, Call it a Comeback: Amicus Fabry Drug Posts Big Study Win at TheStreet
19-Aug-14 04:45PM  FDA Approves Genzymes Cerdelga (eliglustat) Capsules Business Wire
12:10PM  Eli Lilly-Boehringer's Insulin Drug Gets Tentative FDA Nod Zacks
18-Aug-14 08:13AM  Washington Post Off Base In Critiquing Pharma Efforts In Ebola at Forbes
15-Aug-14 09:41AM  Story Stocks from Briefing.com Briefing.com
08:59AM  Story Stocks from Briefing.com Briefing.com
07:14AM  Story Stocks from Briefing.com Briefing.com
14-Aug-14 04:00PM  Merck's Insomnia Drug Belsomra Approved by the FDA Zacks
09:33AM  Stock Market News for August 14, 2014 Zacks
08:46AM  Story Stocks from Briefing.com Briefing.com
08:14AM  Why InterMune (ITMN) Stock Is Down Today at TheStreet
07:44AM  Story Stocks from Briefing.com Briefing.com
13-Aug-14 05:00PM  Sanofi Pasteur Announces Publication of Positive Data for Fluzone® High-Dose Vaccine in The New England Journal of Medicine PR Newswire
12:04PM  Blame MannKind's Fall on its Bloated Balance Sheet at TheStreet
09:53AM  What the Market is Telling MannKind at 24/7 Wall St.
09:08AM  Story Stocks from Briefing.com Briefing.com
08:16AM  Story Stocks from Briefing.com Briefing.com
06:59AM  Story Stocks from Briefing.com Briefing.com
12-Aug-14 10:10AM  Did MannKind Find Right Afrezza Partner in Sanofi? at Barrons.com
10:05AM  MannKind Posts Wider Q2 Loss, Up on Sanofi Deal for Afrezza Zacks
09:59AM  Story Stocks from Briefing.com Briefing.com
08:50AM  Sanofi Launches Authorized Generic Version of Eloxatin® (oxaliplatin injection) PR Newswire
07:24AM  Story Stocks from Briefing.com Briefing.com
11-Aug-14 04:20PM  MannKind Enters into a Global Deal with Sanofi for Afrezza Zacks
12:36PM  [video] Sanofi to Pay MannKind as Much as $925M for Afrezza Global Rights at TheStreet
11:48AM  Jim Cramer's Mad Dash: Good News for Tesla and MannKind at TheStreet
11:25AM  U.S. stocks rise; Kinder Morgan jumps at MarketWatch
10:10AM  MannKind shares soar on Sanofi deal; investors ignore earnings report at MarketWatch
09:59AM  Story Stocks from Briefing.com Briefing.com
09:39AM  U.S. stocks open higher; Kinder Morgan jumps at MarketWatch
09:24AM  Kinder Morgan, MannKind soar; Dean Foods sinks at MarketWatch
09:11AM  MannKind Secures Future of Afrezza in Major Sanofi Deal at 24/7 Wall St.
09:09AM  Priceline's outlook disappoints; Kinder Morgan unites; MannKind shares rocket Hot Stock Minute
09:03AM  U.S. stocks: Futures rise after Fischers dovish remarks at MarketWatch
08:29AM  Stock Market Today: Stock Futures Rise Amid Renewed Dip-Buying TheStreet
Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Its products include Lantus and Apidra analogs of human insulin; Insuman human insulin solutions and suspensions; Amaryl, a sulfonylurea; BGStar, iBGStar, and MyStar Extra blood glucose meters; enzyme replacement therapies, such as Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme, for mucopolysaccharidosis Type I; Aubagio, a immunomodulator for multiple sclerosis; Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; and Jevtana for prostate cancer. The company's products also comprise thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. It also offers Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements to treat pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, as well as through physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has strategic alliances and collaborations with Bristol-Myers Squibb, Regeneron, Warner Chilcott, Regulus Therapeutics Inc., Medtronic, Inc., UCB S.A., and Illumina, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1970 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerJul 15Buy314.92129,10040,656,17622,204,841Jul 17 05:50 PM
Sanofi10% OwnerJul 14Buy318.18150,00047,726,79722,075,741Jul 15 05:45 PM
Sanofi10% OwnerJul 11Buy315.41150,00047,311,83621,925,741Jul 15 05:45 PM
Sanofi10% OwnerJul 10Buy311.08175,00054,439,07321,775,741Jul 14 05:46 PM
Sanofi10% OwnerJul 09Buy308.27195,00060,112,31121,600,741Jul 10 05:45 PM
Sanofi10% OwnerJul 08Buy311.67153,00047,685,74321,405,741Jul 10 05:45 PM
Sanofi10% OwnerJul 07Buy312.90256,70080,320,79521,252,741Jul 08 05:42 PM
Sanofi10% OwnerJul 03Buy311.02100,00031,101,94620,996,041Jul 08 05:42 PM
Sanofi10% OwnerJul 02Buy307.25212,40065,259,55220,896,041Jul 03 06:00 PM
Sanofi10% OwnerJul 01Buy300.20212,40063,761,42120,683,641Jul 03 05:46 PM
Sanofi10% OwnerJun 30Buy282.54212,40060,010,47920,471,241Jul 01 05:39 PM
Sanofi10% OwnerJun 27Buy275.3850,00013,769,09220,258,841Jul 01 05:39 PM
Sanofi10% OwnerMay 19Buy300.04190,75157,233,71620,208,841May 21 05:02 PM
Sanofi10% OwnerMar 28Buy306.73306,94594,149,58320,018,090Mar 31 06:22 PM
Sanofi10% OwnerMar 27Buy311.01306,94595,463,96319,711,145Mar 31 06:21 PM
Sanofi10% OwnerMar 24Buy307.91306,94594,511,73418,790,310Mar 25 06:11 PM
Sanofi10% OwnerMar 21Buy321.22305,11598,008,22218,483,365Mar 25 06:10 PM
Sanofi10% OwnerMar 20Buy328.4157,95719,033,51118,178,250Mar 21 06:21 PM
Sanofi10% OwnerMar 19Buy327.899,7463,195,65118,120,293Mar 21 06:21 PM
Sanofi10% OwnerMar 17Buy328.5560,12819,755,23418,110,547Mar 18 06:58 PM
Sanofi10% OwnerMar 14Buy328.3655,58318,251,21518,050,419Mar 18 06:58 PM
Sanofi10% OwnerMar 12Buy334.69220,99573,964,41217,994,836Mar 14 05:11 PM
Sanofi10% OwnerMar 11Buy332.26180,71060,043,33617,773,841Mar 12 05:36 PM
Sanofi10% OwnerMar 10Buy328.73199,82265,687,43517,593,131Mar 12 05:36 PM
Sanofi10% OwnerMar 07Buy332.51241,81880,405,73317,393,309Mar 10 09:52 PM
Sanofi10% OwnerMar 07Buy316.2069,87322,093,65517,151,491Mar 10 09:51 PM
Sanofi10% OwnerMar 06Buy339.6080,40427,305,54617,081,618Mar 10 09:51 PM
Sanofi10% OwnerMar 03Buy338.12251,59485,070,11817,001,214Mar 05 08:36 PM
Sanofi10% OwnerFeb 07Buy287.3421,9866,317,45516,749,620Feb 10 06:46 PM
Sanofi10% OwnerFeb 06Buy286.70146,52542,008,39016,727,634Feb 10 06:46 PM
Sanofi10% OwnerFeb 05Buy282.00206,97858,367,10716,581,109Feb 06 07:30 PM
Sanofi10% OwnerFeb 04Buy286.44190,28654,504,78916,374,131Feb 06 07:30 PM
Sanofi10% OwnerFeb 03Buy283.46198,05856,141,71916,183,845Feb 04 07:11 PM
Sanofi10% OwnerJan 31Buy289.6610,9143,161,38315,985,787Feb 04 07:11 PM
Sanofi10% OwnerJan 28Buy278.5483,23523,184,32115,974,873Jan 29 08:20 AM
Sanofi10% OwnerJan 27Buy272.9674,68520,386,04415,891,638Jan 29 08:20 AM